Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6187MR)

This product GTTS-WQ6187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6187MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4737MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ3159MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ9076MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ8308MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ9182MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ2809MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ2862MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ15618MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW